Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 2 Corporate Overview J.P. Morgan Healthcare Conference 2026 January 14, 2026 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements of historical facts, including statements regarding our future ...

Core Viewpoint - SAB Biotherapeutics, Inc. has appointed David Zaccardelli, Pharm.D. as Chair of the Board and Rita Jain, M.D. as an independent director, which is expected to enhance the company's strategic direction and growth potential in developing therapies for autoimmune diseases, particularly Type 1 Diabetes (T1D) [2][4][5]. Group 1: Appointments and Expertise - David Zaccardelli brings over 20 years of biopharmaceutical experience, having successfully led companies from clinical stages to commercialization, including the launch of Ohtuvayre, a notable biotech product [4][8]. - Rita Jain has more than two decades of leadership experience in biopharmaceutical development, particularly in autoimmune and inflammatory diseases, and has held key positions in various companies [6][9]. Group 2: Company Focus and Product Development - SAB Biotherapeutics is focused on developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, with its lead candidate, SAB-142, aiming to modify the disease progression in T1D patients [2][10]. - The company utilizes advanced genetic engineering and proprietary technology to produce high-potency human immunoglobulin G (hIgG) without the need for human donors, which positions it to address significant unmet medical needs [10].

Core Insights - MannKind Corporation reported a 17% increase in Q3 2025 revenues to $82.1 million compared to Q3 2024, driven by higher royalties and product sales [6][9][14] - The acquisition of scPharmaceuticals is expected to enhance MannKind's commercial capabilities and accelerate revenue growth [2][7] - The FDA has accepted the sBLA for Afrezza in the pediatric population, with a PDUFA date set for May 29, 2026 [6][7] Financial Performance - Q3 2025 revenues reached $82.1 million, a $12.1 million increase from Q3 2024, with royalties up 23% to $33.3 million and Afrezza sales up 23% to $18.5 million [9][12] - Year-to-date revenues for 2025 totaled $237.0 million, reflecting a 14% increase compared to the same period in 2024 [14] - The company reported a net income of $8.0 million for Q3 2025, down from $11.6 million in Q3 2024, while non-GAAP net income increased by 45% to $22.4 million [16][23] Business Developments - The acquisition of scPharmaceuticals was completed on October 7, 2025, which is anticipated to diversify and accelerate revenue growth, particularly through the FUROSCIX product [6][7] - The company initiated a Phase 2 clinical trial for MNKD-201 in idiopathic pulmonary fibrosis (IPF) and plans to enroll the first patient in Q1 2026 [5][6] - MannKind's MNKD-101 Phase 3 trial achieved interim enrollment targets ahead of schedule, with an interim analysis expected mid-year 2026 [6][7] Research and Development - Research and development expenses increased by 9% in Q3 2025, primarily due to ongoing clinical trials and patient enrollment [12][17] - The company is advancing its investigational molecule under collaboration with United Therapeutics and has planned pre-clinical studies for Bumetanide DPI [11][17] Cash and Investments - As of September 30, 2025, MannKind had cash, cash equivalents, and investments totaling $286.3 million, with significant cash utilized for the acquisition of scPharmaceuticals [11][12] - The company reported an impairment of available-for-sale investment of $6.4 million for Q3 2025 due to the write-off of the Thirona investment [16][23]

Liquidia R&D Day Webcast presentation October 28, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and fina ...

Core Insights - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biopharmaceutical company focused on developing and acquiring technologies for medicine discovery and development [1] - The company operates in a competitive landscape with peers including Neurocrine Biosciences, Incyte Corporation, Alkermes plc, Myriad Genetics, and United Therapeutics Corporation [1] Financial Performance - Ligand's Return on Invested Capital (ROIC) is -3.48%, which is below its Weighted Average Cost of Capital (WACC) of 7.60%, indicating insufficient returns to cover capital costs [2] - Neurocrine Biosciences has a ROIC of 9.78% and a WACC of 5.47%, resulting in a ROIC to WACC ratio of 1.79, demonstrating effective capital utilization [3] - Incyte Corporation and United Therapeutics Corporation also exhibit strong ROIC to WACC ratios of 2.50 and 2.28, respectively, indicating efficient capital management [3] - Alkermes plc has the highest ROIC to WACC ratio of 2.93, suggesting it generates returns significantly above its cost of capital, making it an attractive investment [4] - Myriad Genetics shows a negative ROIC of -71.95% against a WACC of 10.96%, resulting in a ROIC to WACC ratio of -6.57, highlighting severe inefficiencies in capital utilization [4]

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that affected investors between August 13, 2024, and May 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [2]. - It is alleged that updated milestone criteria in the partnership with United Therapeutics Corporation would negatively impact the revenue from the Company's regenerative medicine program [2]. - As a result, the Company's public statements were materially false and misleading during the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 12, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions by the company during the specified class period [1][2]. Group 1: Allegations - The complaint alleges that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [1]. - It is also claimed that updated milestone criteria in the partnership with United Therapeutics Corporation would negatively impact the company's regenerative medicine program revenue [1]. - As a result, the company's public statements were materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially be appointed as lead plaintiff [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of 3D Systems Corporation during the specified Class Period of the upcoming lead plaintiff deadline on August 12, 2025, and the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought 3D Systems securities between August 13, 2024, and May 12, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 12, 2025 [2][6]. - The lawsuit alleges that 3D Systems made false and misleading statements regarding its business performance and the impact of customer spending, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of 3D Systems Corporation during the Class Period from August 13, 2024, to May 12, 2025, about the lead plaintiff deadline on August 12, 2025, for a class action lawsuit [1][4]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The lawsuit alleges that 3D Systems made false and misleading statements regarding its business performance and the impact of customer spending [4]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].